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Abstract
Background: Porphyria cutanea tarda (PCT) is a skin disorder originating from a deficit of the liver enzyme
uroporphyrinogen decarboxylase. PCT may be a risk factor for hepatocellular carcinoma (HCC) and other cancers,
but the evidence is unclear. We aimed to investigate cancer and premature mortality risk in persons with PCT.
Methods: The cohort study consisted of all Norwegian residents from 18 years between 2000 and 2016 (n = 5.4 million).
612 persons with PCT, and all cancer diagnoses and causes of death were identified through record linkage between
national registries. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were adjusted for age, sex,
education and calendar years. We additionally compared persons with PCT to persons with a history of chronic alcohol
abuse (n = 30,468).
Results: Persons with PCT were more likely to be diagnosed with HCC [adjusted HR (aHR) = 19.7, CI = 8.8–44.0) and
gallbladder and biliary tract cancer (aHR = 6.8, CI = 2.2–21.0) than the reference population. A moderate increased risk for
HCC (aHR = 3.1, CI = 1.2–7.7) and gallbladder and biliary tract cancer (aHR = 4.0, CI = 1.1–14.4) remained when compared
to persons with a history of chronic alcohol abuse. Additionally, compared to the reference population, persons with
PCT had an increased risk of premature death (aHR = 1.5, CI = 1.2–1.7), due to the following causes of death: malignant
neoplasms (aHR = 1.4, CI = 1.0–1.9), diseases of the liver (HR = 5.5, CI = 2.5–12.2), and drug and alcohol overdose (HR = 9.9,
CI = 4.7–20.8).
Conclusions: Persons with PCT had an increased risk of HCC and cancer of the gallbladder and biliary tract, as well as
premature death. Although most of our findings can likely be explained by common lifestyle risk factors, something
inherent in PCT may contribute to the development of HCC.
Keywords: Porphyria cutanea tarda, Neoplasms, Liver neoplasms, Hepatocellular carcinoma, Gallbladder and bile duct
neoplasms, Cause of death
Background
Porphyria cutanea tarda (PCT) results from a defect of hep-
atic enzyme uroporphyrinogen decarboxylase (UROD). The
impaired UROD activity in the liver causes accumulation of
uro and heptacarboxylated porphyrins, which act as photo-
sensitizer in the skin and give symptoms in the form of bul-
lae, fragile skin, hypertrichosis and hyperpigmentation [1].
PCT is the most prevalent form of porphyria worldwide,
with symptom debut typically in middle age and an ap-
proximate equal sex ratio. In Norway, the prevalence is es-
timated at 1 in 10,000 [2]. PCT occurs in both an
acquired (sporadic PCT) and a hereditary form (familial
PCT) [3], which are clinically indistinguishable. Suscepti-
bility factors for both include excess iron, hepatitis C and
B infection, excessive alcohol intake, smoking, human im-
munodeficiency virus (HIV) and oestrogens [3–8], al-
though susceptibility factors appear less strongly
correlated with familial PCT [3, 6]. PCT is associated with
hepatocellular carcinoma (HCC) [9–12], and persons with
PCT may also have increased risk of premature death
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[12]. The main risk factors for HCC in the general popula-
tion include Hepatitis C and B and an excessive alcohol
intake [13, 14]. Whether PCT increases the risk for HCC
over and above the risk caused by associated susceptibility
factors is controversial. It also remains unclear whether
the risk for HCC warrants HCC surveillance, as indicated
for other types of hepatic porphyrias [15].
We aimed to investigate risks of cancer and premature
mortality in persons with PCT compared to the general
population, and to examine whether any increased risk
was likely caused by PCT associated susceptibility factors
or, in part, PCT itself.
Methods
Data sources
Data collection was derived from five nationwide Norwe-
gian population based sources: The Norwegian Porphyria
Registry [16], The Cancer Registry of Norway [17], The
Cause of Death Registry of Norway [18], Statistics Norway,
and the Norwegian Labour and Welfare Administration.
Using a unique national 11-digit personal identification
number, record linkage was performed in 2018.
Persons in Norway who are diagnosed with porphyria
are invited to participate in the national Norwegian Por-
phyria Registry, administered by the Norwegian Porphy-
ria Centre, established in 2000 [16]. Data is derived from
patient-reported questionnaires supplemented with bio-
chemical and genetic laboratory results. Data included in
this report were updated one or two years after the first
questionnaire, and thereafter every four years.
The mandatory national Norwegian Cancer Registry, re-
cords all new neoplasms since 1953. Diagnoses are based
on a modified version of the 7th revision of the Inter-
national Classification of Diseases (ICD-7), and complete-
ness is greater than 98% [17]. The Cause of Death Registry
of Norway has a coverage greater than 98% [18]. Diagnos-
tic codes are based on ICD-9 and ICD-10.
Statistics Norway has maintained the Population Database,
with demographic data for the entire population, since 1876,
and The Norwegian Standard Classification of Education,
with information about educational attainment, since 1970.
Statistics Norway and Norwegian Labour and Welfare
Administration have maintained records regarding ac-
cess to social security benefits: sick leave benefit, the
disability pension, and medical and occupational -
rehabilitation benefit since 1992. Diagnostic codes
include the second revision of the International Classifi-
cation of Primary Care (ICPC-2), ICD-9 and ICD-10.
Study population
All Norwegian residents, registered in the Norwegian
Population Registry and 18 years or older from 2000 to
2016 were included in our cohort, and the reference
population comprised of 5,451,951 adults. Of the 790
persons with a known overt diagnosis of PCT in
Norway, registered at the Norwegian Porphyria Centre,
alive and aged 18 years or older between January 2000
and December 2016, 612 (78%) agreed to participate
(Fig. 1). Where a cancer diagnosis was the outcome, we
excluded 23 persons who had a cancer diagnosis pro-
ceeding PCT symptoms (Fig. 1).
PCT diagnosis was based on biochemical testing per-
formed at the Department of Medical Biochemistry and
Pharmacology, Haukeland University Hospital [3], apply-
ing diagnostic algorithms as described by Badminton
and colleagues [19]. Urinary porphyrins were expressed
in nmol/mmol creatinine. Sequencing of the UROD gene
was performed at the Center for Medical Genetics and
Molecular Medicine at Haukeland University Hospital to
determine if the patient had familial or sporadic PCT.
Participants where DNA analysis had not been per-
formed, were registered as unclassified PCT.
For our sub-group analyses, we identified 30,468
persons with a diagnosis of chronic alcohol abuse/
Fig. 1 Overview of study sample
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dependence through the Norwegian Labour and Welfare
Administration registrations of social security benefits.
Disease classification
Primary cancer diagnoses and underlying causes of death
of theoretical interest, or with a count of three or
greater, were investigated. This resulted in the following
primary cancers: all sites (ICD-7: 140–207; ICD-10:
C00–96, D45–47), colon/rectum (ICD-7: 153–154;
ICD-10: C18-C21), HCC (ICD-7: 155.0; C22.0), gallblad-
der and biliary tract (ICD-7: 156; ICD-10:C23–24), pan-
creas (ICD-7: 157; ICD-10; C25), lung (ICD-7: 162;
C33–34); non-melanoma skin (ICD-7: 191; ICD-10:
C44), breast (ICD-7: 170; ICD-10: C50), prostate (ICD-7:
177; ICD-10: C61), and leukemia (ICD-9: 207; ICD-10:
C91–95, D45–47). We included any new cases of pri-
mary cancer diagnosis from January 2000. We also
assessed second primary cancers specifically. Similarly,
the following underlying causes of death were investi-
gated: malignant neoplasms (ICD-10: C00–96, D45–47),
diabetes mellitus (ICD-10: E10–14), ischemic heart disease
(ICD-10: I20–25), cerebrovascular diseases (ICD-10:
I60-I69), chronic obstructive pulmonary disease (ICD-10:
J43-J44), diseases of the liver (ICD-10: K70–77, B15–19,
E83.1), renal failure (ICD-10: N17–19), and alcohol or
drug overdose (ICD-10: X40–49). Chronic alcohol abuse/
dependence was defined by the following codes: ICPC-2:
P15; ICD-9: 303, 305.0; ICD-10: F10.
Statistical analysis
Stata/SE Version 14 for Windows was used for all statis-
tical analyses (StataCorp Stata Statistical, Software: Re-
lease 14, College Station, TX, USA). Annual incidence
was calculated by dividing the number of new cases by
the total person-years of all participants. The entry time
was age at baseline or 18 if younger than 18 years in
2000 (i.e., left truncated). The exit time was age at event
(cancer/mortality) or censoring (death due to other fac-
tors, or end of study follow-up in 2016, whichever oc-
curred first). To assess the relationship between PCT
and cancer/mortality, a Cox regression was used to
estimate the hazard ratios (HRs) with 95% confidence
intervals (CIs), in which PCT diagnosis (no/yes) was
the exposure and the cancer or cause of death of
interest (no/yes) the outcome. Where numbers permitted,
we additionally investigated PCT type (0 = reference,
1 = sporadic PCT, 2 = familial PCT, 3 = PCT type
unclassified PCT) as the exposure. Age was used as the
time scale, stratifying the model by birth cohorts (< 1937,
1937–1960, 1961–1983, > 1983), to adjust for calendar ef-
fects. The multivariate models were adjusted for sex, age
(as the time-scale), and educational attainment. The pro-
portionality assumption was assessed and covariates en-
tered as time-dependent when the assumption was
violated. Obtained level of education was categorized into:
no schooling, compulsory education (year 1–10), upper
secondary education (11–13, or 14 years if including
post-secondary non-tertiary education), tertiary education
(14+ years), and unspecified/missing. Interactions of ex-
posure by educational obtainment (tertiary or upper sec-
ondary vs less education) and by sex were explored, and
none were found (although limited power for interaction
analyses). Differences in age at time of death were investi-
gated by independent samples t-tests.
For each adjusted hazard ratio (aHR), we calculated
the corresponding evidence value (E-value). The E-value
is defined as the minimum risk ratio an unmeasured
confounder requires to explain away the outcome and is
calculated by the formula: E-value = hazard ratio (HR) +
sqrt[HR x (HR-1)] [20].
We compared cancer and causes of death risk in per-
sons with PCT to persons with a history of chronic alco-
hol abuse/dependence, who have a high mortality risk.
This was achieved by conducting a competing risks re-
gression survival analysis calculating the adjusted
subdistribution hazard ratio (aSHR). Persons with both
PCT and a history of chronic alcohol abuse/dependence
(n = 17) were excluded.
Ethical approval
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki and was approved by
the Regional Committees for Medical and Health Re-
search Ethics, Norway (reference number: 2012/753).
Results
At entry into the study, persons with familial PCT, spor-
adic PCT and unclassified PCT were, on average, 9, 14
and 21 years older than the reference population, re-
spectively. Additionally, persons with sporadic and un-
classified PCT types, generally had less education and
were more likely to smoke daily, and have type II dia-
betes than persons with familial PCT. However, there
was no apparent difference regarding self-reported alco-
hol use (Table 1).
Persons with PCT had, on average, a 20-fold increased
risk of HCC and an 7-fold increased risk of gallbladder
and biliary tract cancer, compared to the general popula-
tion. There was no evidence of an increased risk of all
first primary cancers in persons with PCT, but we ob-
served a 2-fold increased risk of all second primary can-
cer diagnoses. When assessed by PCT type (sporadic,
familial, unclassified PCT), the risk was greatest in per-
sons with unclassified PCT type (Table 2). The individ-
ual characteristics of persons with PCT and cancers are
displayed in Additional file 1: Table S1.
The mean age at death for persons with PCT was 72.2
years (95% CI: 70.3–74.1) compared to 78.5 years (95%
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CI: 78.4–78.5) in the general population (mean difference
= 6.3, 95% CI: 4.4–8.2, p < .001). There was no detectable
difference in the mean age at death between persons with
sporadic PCT (mean = 71.8; 95% CI: 68.9–74.7), familial
PCT (mean = 72.1; 95% CI: 67.0–77.1) and unclassified
PCT type (mean = 73.3; 95% CI: 70.5–76.1).
Compared to the general population, persons with PCT
had, on average, a 50% increased risk of premature death,
40% increased risk of death by malignant neoplasms (all--
sites), a 6-fold excess risk of death by liver diseases, and a
10-fold excess risk of death by alcohol or drug overdose.
The risk of premature death and death by malignancies
was highest in persons with unclassified PCT (Table 3).
Compared to persons with a history of chronic alcohol
abuse/dependence, persons with PCT were at a 3-fold
increased risk of HCC and 4-fold increased risk of gall-
bladder and biliary tract cancer, and had an 80% reduced
risk of dying from non-malignant liver diseases
(Table 4).
Discussion
We found a 20-fold increased risk of HCC and a 7-fold in-
creased risk of gallbladder and biliary tract cancer in per-
sons with PCT compared to the general population. An
increased risk remained also when comparing to persons
with a history of chronic alcohol abuse/dependence. Fur-
ther, persons with PCT had an overall 50% increased risk
of premature mortality compared to the general popula-
tion with 6- and 10-fold increased risks of dying from liver
disease and drug or alcohol overdose, respectively.
Table 1 Baseline characteristics of participants with sporadic (s-PCT), familial (f-PCT) and unclassified PCT compared to the reference









n Valid % N Valid % n Valid % n Valid %
Sex – male 125 49.0 122 47.9 46 45.1 2713,666 50.2
Age in years at study start (mean, SD) 52.8 (10.9) 47.5 (13.7) 60.1 (13.9) 38.9 (22.2)
Highest level of education obtained
Not specified 4 1.6 2 0.8 0 0 649,456 11.9
No schooling, primary/middle education (year 1–10) 90 35.3 55 21.6 46 45.1 1334,399 24.8
Upper secondary education (11–12, 13 or 14 years) 124 48.6 123 48.2 43 42.2 1994,025 36.6
Tertiary education (14+ years) 37 14.5 75 29.4 13 12.8 1474,130 27.0
Lifestyle factors
Alcohol use (yes) 163 93.6 173 93.5 35 87.5
Alcohol – amount of standard drinks per week (mean, SD) 1.7 (1.3) 1.6 (1.3) 1.5 (1.3)
Tobacco: cigarettes (yes) 83 32.6 50 19.6 30 61.2
Never smoked / have quit 65 37.8 127 69.4 22 53.63
Occasional smokers/ daily smokers 107 62.2 56 30.6 19 46.3
Amount of cigarettes consumed per day (mean, SD) 2.8 (6.2) 1.2 (3.8) 1.7 (4.6)
Body mass index (BMI)
Underweight (BMI Under 18.5) 8 4.8 5 2.8 2 5.1
Normal (BMI between 18.5 and 25) 67 40.4 56 30.9 13 33.3
Overweight (BMI between 25 and 30) 68 41.0 90 49.7 21 53.8
Obese (BMI of 30 or greater) 23 13.9 30 16.6 3 7.7
Other diseases
Liver disease 24 11.0 12 5.2 6 5.2
Haemochromatosis 11 5.1 12 5.2 2 4.1
Type II diabetes 11 5.1 3 1.3 2 7.4
Biochemical characteristics
Total porphyrins (mean, 95% CI) 880.5 803.6–957.5 941.6 835.7–1047.5 989.2 660.58–1317.81
Uroporphyrin (mean, 95% CI) 608.5 553.5–663.4 706.1 625.03–787.1 768.45 504.01–1032.89
Abbreviations: PCT porphyria cutanea tarda
Lifestyle factors are based on self-reported questionnaires sent to the Norwegian Porphyria Registry. 500 of 612 responded to the questionnaire. Biochemical characteristics
are based on the highest ever recorded value (generally at time of diagnosis). Urinary porphyrins were expressed in nmol/mmol creatinine (upper reference limit < 30).
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diagnosis per 100 (95% CI)
Hazard ratios (95% confidence intervals) E-value
Crude Adjusted
All sites – first primary C (140–207; C00–96, D45–47)
Reference 358,701/5451951 70,185,262; 0.507 (0.506–0.509) 1.0 1.0 1.0
PCT (total) 80/589 8368; 0.956 (0.768–1.190) 1.1 (0.9–1.4) 1.1 (0.9–1.3) 1.4
Familial PCT 25/245 3728; 0.671 (0.453–0.992) 0.9 (0.6–1.4) 0.9 (0.6–1.3) 1.0
Sporadic PCT 34/243 3547; 0.959 (0.685–1.342) 1.1 (0.8–1.5) 1.0 (0.7–1.4) 1.1
Unclassified PCT 21/101 1094; 1.920 (1.252–2.945) 1.8 (1.1–2.7) 1.6 (1.0–2.5) 2.6
All sites – second primary C (140–207; C00–96, D45–47)
Reference 57,505/5451951 71,305,121; 0.081 (0.080–0.081) 1.0 1.0 1.0
PCT (total) 26/589 8424; 0.309 (0.210–0.453) 2.4 (1.6–3.5) 2.2 (1.6–3.3) 3.8
Familial PCT 6/245 3749; 0.160 (0.72–0.356) 1.5 (0.7–3.3) 1.4 (0.6–3.1) 2.2
Sporadic PCT 14/243 3557; 0.394 (0.233–0.665) 2.9 (1.7–4.9) 2.8 (1.7–4.7) 5.0
Unclassified PCT 6/101 1119; 0.536 (0.241–1.194) 2.8 (1.2–6.1) 2.5 (1.1–5.6) 4.4
Colon/rectum (153–154; C18-C21)
Reference 46,077/5451951 71,375,873; 0.503 (0.501–0.504) 1.0 1.0 1.0
PCT 11/578 8564; 0.936 (0.752–1.165) 1.2 (1.0–1.5) 1.1 (0.9–1.4) 1.4
Hepatocellular carcinoma (155.0; C22.0)
Reference 1543/5451951 71,538,150; 0.002 (0.002–0.002) 1.0 1.0 1.0
PCT (total) 6/589 8567; 0.070 (0.031–0.156) 19.9 (8.9–44.3) 19.7 (8.8–44.0) 38.9
Gallbladder and biliary tract (156; C23-C24)
Reference 1628/5451951 71,537,477; 0.003 (0.003–0.003) 1.0 1.0 1.0
PCT 3/589 8576; 0.035 (0.011–0.108) 7.2 (2.3–22.5) 6.8 (2.2–21.0) 13.0
Pancreas (157, C25)
Reference 9830/5451951 71,375,873; 0.014 (0.014–0.014) 1.0 1.0 1.0
PCT 3/589 8546; 0.035 (0.011–0.109) 1.6 (0.5–4.9) 1.5 (0.5–4.6) 2.4
Lung (162, C33–34)
Reference 34,920/5451951 71,498,290; 0.049 (0.048–0.049) 1.0 1.0 1.0
PCT 13/589 8571; 0.152 (0.088–0.261) 2.9 (1.7–5.0) 1.6 (0.9–2.8) 2.6
Non-melanoma skin (191, C44)
Reference 16,048/5452,951 66,463,540; 0.024 (0.024–0.0024) 1.0 1.0 1.0
PCT 4/589 8533; 0.047 (0.018–0.125) 1.9 (0.7–5.1) 1.1 (0.4–3.5) 1.4
Breast (170; C50)
Reference 39,581/2713314 35,414,769; 0.112 (0.111–0.113) 1.0 1.0 1.0
PCT 5/299 4337; 0115 (0.048–0.277) 0.6 (0.3–1.5) 0.6 (0.3–1.7) 1.0
Prostate (177; C61)
Reference 56,652/2738637 35,644,567; 0.158 (0.157–0.159) 1.0 1.0 1.0
PCT 14/290 4170; 0.336 (0.199–0.567) 1.2 (0.7–2.0) 1.1 (0.6–1.8) 1.4
Leukaemia (207; C91–95, D45–47)
Reference 16,349/5451951 72,014,044; 0.023 (0.022–0.023) 1.0 1.0 1.0
PCT 4/589 8560; 0.023 (0.018–0.125) 1.4 (0.5–3.7) 1.3 (0.5–3.5) 1.1
Crude analysis adjusted for age as the time-scale. Adjusted analysis covariates include age as time-scale, sex (except for gender specific cancers), educational
obtainment, and birth cohorts.
Note that 23 persons diagnosed with cancer prior to their first reported PCT symptoms or diagnosis were excluded. Diagnosis based on the International
Classification of Diseases, 7th (ICD-7) and 10th revision (ICD-10) codes.
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A similar excess risk for HCC has been reported from
a combined registry cohort study of 530 PCT inpatients
from Sweden and Denmark [12]. Although the relative
risk of HCC in our study was high when compared to
the general population, the annual incidence rate
(absolute risk) could be considered low at 0.07%, consid-
ering that HCC risk factors are prominent among per-
sons with PCT. However, Norway has one of the lowest
prevalence’s of HCC and chronic hepatitis B and C
across Europe [21–23]. Therefore, the proportion of




rate per 100 (95% CI)
Hazard ratios (95% confidence intervals) E-value
Crude Adjusted
Premature death
Reference 748,900/5451,951 71,559,947; 1.047 (1.044–1.049) 1.0 1.0 1.0
PCT (total) 158/612 8921; 1.771 (1.515–2.070) 1.5 (1.3–1.8) 1.5 (1.2–1.7) 2.4
Familial PCT 27/255 3933; 0.686 (0.471–1.001) 0.7 (0.5–1.1) 0.8 (0.1–1.1) 1.0
Sporadic PCT 64/255 3828; 1.672 (1.309–2.136) 1.5 (1.2–1.9) 1.4 (1.1–1.8) 2.2
Unclassified PCT 67/102 1160; 5.776 (4.546–7.339) 2.6 (2.1–3-4) 2.5 (1.9–3.1) 4.4
Malignant neoplasms (C00–96)
Reference 181,205/5,451,951 71,559,947; 0.254 (0.253–0.255) 1.0 1.0 1.0
PCT (total) 48/612 8921; 0.538 (0.405–0.714) 1.4 (1.1–1.9) 1.4 (1.0–1.9) 2.2
Sporadic PCT 23/255 3828; 0.601 (0.399–0.904) 1.6 (1.0–2.4) 1.5 (1.0–2.2) 2.4
Familial PCT 11/255 3933; 0.280 (0.155–0.505) 0.9 (0.5–1.7) 0.9 (0.5–1.6) 1.0
Unclassified PCT 14/102 1160; 1.207 (0.715–2.038) 2.0 (1.2–3.4) 1.8 (1.1–3.1) 3.3
Diabetes mellitus (E10–14)
Reference 11,826/5452,010 71,559,947; 0.016 (0.016–0.017) 1.0 1.0 1.0
PCT 3/612 8921; 0.034 (0.011–0.104) 2.0 (0.7–6.3) 1.7 (0.5–5.3) 2.8
Ischemic heart disease (I20–25)
Reference 5,451,951 71,559,947; 0.135 (0.134–0.136) 1.0 1.0 1.0
PCT 7/612 8921; 0.079 (0.037–0.165) 0.6 (0.3–1.2) 0.6 (0.3–1.2) 1.0
Cerebrovascular diseases (I60-I69)
Reference 57,639/5,451,951 71,559,947; 0.081 (0.080–0.081) 1.0 1.0 1.0
PCT 8/612 8915; 0.090 (0.045–0.179) 1.2 (0.6–2.4) 1.1 (0.6–2.3) 1.4
Chronic obstructive pulmonary disease (J43–44)
Reference 31,172/5,451,951 71,559,947; 0.043 (0.043–0.044) 1.0 1.0 1.0
PCT 7/612 8921; 0.078 (0.037–0.165) 1.4 (0.6–2.9) 1.4 (0.6–2.8) 2.2
Diseases of the liver (K70–77, B15–19, E83.1) a
Reference 4661/5,452,010 71,559,947; 0.007 (0.00–0.007) 1.0 1.0 1.0
PCT 6/612 8921; 0.067 (0.030–0.150) 5.9 (2.7–13.2) 5.5 (2.5–12.2) 10.5
Renal failure (N17–19)
Reference 6686/5,452,010 71,559,947; 0.009 (0.009–0.010) 1.0 1.0 1.0
PCT 2/612 8921; 0.022 (0.006–0.090) 2.9 (0.7–11.8) 2.9 (0.7–11.7) 5.3
Drug and alcohol overdose (X40–49) b
Reference 4961/5452,010 71,559,947; 0.007 (0.007–0.007) 1.0 1.0 1.0
PCT 7/612 8921; 0.078 (0.037–0.165) 12.1 (5.8–25.5) 9.9 (4.7–20.8) 19.3
Disease codes defined using the International Statistical Classification of Diseases 10th (ICD-10) revision
aSpecific diagnoses of the 6 PCT patients with liver disease were: alcoholic cirrhosis of liver (K70.3), alcohol hepatic failure (K70.4) primary biliary cirrhosis (K74.3),
hepatic failure (K72.9), 2 x chronic viral hepatitis C (B18.2). Familial PCT, n=0, sporadic PCT, n=2, Not tested, n=3. None of the six persons with liver disease were
diagnosed with HCC or gallbladder and biliary tract cancer.
bSpecific diagnosis of the 7 persons with PCT and drug and alcohol overdose included: 4 x accidental poisoning by and exposure to narcotics and psychodysleptics
[hallucinogens], not elsewhere classified (ICD-10: X42); 1 x accidental poisoning by and exposure to non-opioid analgesics, antipyretics and antirheumatics (ICD-10: X40);
1 x accidental poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified (ICD-10: X41); 1 x
accidental poisoning by and exposure to alcohol (X45). Familial PCT, n=1, sporadic PCT, n=3, Not tested, n=3
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persons with PCT in Norway precipitated by a common
HCC risk factor is likely lower than countries where
such risk factors are more frequent (which is supported
by the proportionally larger group of familial PCT in
Norway). Consequently, it is likely that annual incidence
rates of HCC in persons with PCT are higher in
non-Scandinavian countries. We found in addition to
HCC, a 7-fold increased risk of gallbladder and biliary
tract cancer, which, to our knowledge, has only been re-
ported once before in a case-report [24]. We also found
13 persons with PCT and lung cancer, which implied a
non-significant excess risk of 60%.
Fracanzani and colleagues found that having PCT re-
sulted in a 5-fold increased risk of HCC in 53 PCT pa-
tients compared to age, sex, liver disease severity and
hepatitis C infection matched control patients with
chronic liver disease [11]. However, the study may have
suffered from selection bias as PCT patients were drawn
from a single liver unit with a 90% prevalence of hepa-
titis C infection. In our population based cohort study,
we found a 3-fold increased risk of HCC in persons with
PCT, when compared to persons with a history of
chronic alcohol abuse/dependence. Typically, alcohol
abuse/dependence and liver disease, such as hepatitis C,
may lead to cirrhosis and eventual HCC. Interestingly,
we found that although HCC risk was greater, persons
with PCT had an 80% reduced risk of dying from
non-malignant liver diseases, such as viral hepatitis or
liver cirrhosis, than this control group. This finding sug-
gests that something specific to PCT may contribute to
the development of HCC independent of, or by inter-
action with, liver disease and an excessive alcohol intake.
In line with Linet and colleagues, who reported a 70%
excess risk of premature death for persons with PCT in
their study [12], we found a 50% excess risk. When
stratified by PCT type, however, this increased risk was
only evident in persons with sporadic or unclassified
PCT. We also found that having PCT resulted in a
6-fold increased risk of dying from liver diseases com-
pared to the general population. Similarly, Linet and
Table 4 Annual incidence/mortality rates and subdistribution hazard ratios for malignancies and causes of death in persons with




rate per 100 (95% CI)
Subdistribution hazard ratios (95% confidence intervals)
Crude SHR (95% CI) Adjusted SHR (95% CI)
All sites – first primary C (C00–96, D45–47)
Reference 3549/30468 393,347; 0.902 (0.873–0.932) 1.0 1.0
PCT 78/572 8132; 0.959 (0.768–1.198) 0.7 (0.5–0.8) 0.7 (0.6–0.9)
HCC (155.0; C22.0)
Reference 80/30,468 402,342; 0.020; 0.020 (0.16–0.025) 1.0 1.0
PCT 5/572 8330; 0.060 (0.025–0.144) 2.2 (0.9–5.5) 3.1 (1.2–7.7)
Gallbladder & biliary tract (156; C23–24)
Reference 19/30,468 402,403; 0.003 (0.003–0.007) 1.0 1.0
PCT 3/572 8339; 0.036 (0.012–0.112) 4.4 (1.3–15.0) 4.0 (1.1–14.4)
All-cause mortality
Reference 11,756/30468 402,757; 2.919 (2.867–2.972) 1.0 1.0
PCT 150/595 8684; 1.728 (1.472–2.027) 0.4 (0.3–0.4) 0.4 (0.4–0.5)
Diseases of the liver (K70–77, B15–19, E83.1)
Reference 735/30468 402,746; 0.182 (0.170–0.196) 1.0 1.0
PCT 4/595 8683; 0.046 (0.017–0.123) 0.2 (0.1–0.6) 0.2 (0.1–0.6)
Malignant neoplasms (C00–96)
Reference 2323/30,468 402,746; 0.577 (0.554–0.601) 1.0 1.0
PCT 45/595 8683; 0.518 (0.387–0.694) 0.5 (0.4–0.7) 0.6 (0.4–0.8)
Drug and alcohol overdose (X40–49)
Reference 484/30,468 402,746; 0.134 (0.134–0.157) 1.0 1.0
PCT 5/597 8.683; 0.058 (0.024–0.138) 0.5 (0.2–1.1) 0.5 (0.2–1.2)
Disease codes defined using the International Classification of Primary Care – 2nd Edition (ICPC-2) and the International Statistical Classification of Diseases 7th (ICD-7)
and 10th (ICD-10) revisions. Reference group = Chronic alcohol abuse/dependence (ICD-10 = F10, ICD-9 = 303, 305.0, ICPC2 = P15). 17 persons with both PCT and a
diagnosis of chronic alcohol abuse or dependence, including one person with HCC, were excluded from the analyses. 23 persons with a cancer diagnosis prior to their
PCT diagnosis were excluded from any analysis in which cancer was the outcome
Mean age at death for persons with chronic alcohol abuse = 63.6 (SD: 11.7) vs. PCT = 72.5 (SD = 11.7), proportion of males = 78% vs. PCT = 50%
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colleagues found increased odds of dying from cirrhosis
of the liver in persons with PCT [12]. Lastly, we found
an 10-fold excess risk of mortality from alcohol or drug
overdose, which, to our knowledge, has not been previ-
ously reported.
Strengths and weaknesses
Major strengths of our study are the population-based co-
hort design, the use of valid information from compulsory
national registries, and a long period of follow-up. Persons
with PCT were drawn from a nationwide registry with a
good participation rate (78%). However, it is possible that
participants differed from non-participants and thus selec-
tion bias may affect the validity of the results. Given the
complex relationship between PCT and cancer, we chose
to exclude cancer cases preceding PCT. This design re-
duces the risk of selection and information bias. We ex-
tend previous analyses by adjusting for education (as a
proxy of socioeconomic position and lifestyle), comparing
outcomes for patients with familial, sporadic and unclassi-
fied PCT, and comparing risks of PCT patients with per-
sons with a history of alcohol abuse/dependence. A
limitation of the study was the small numbers of cases.
We also did not have access to liver biopsies of patients
with HCC or gallbladder and biliary tract cancer. There-
fore, we are uncertain regarding the proportion of these
persons with concurrent fibrosis/cirrhosis.
Several common causes of PCT and cancer exist, such as
alcohol use, liver disease and smoking. This information is
not available in our study for the general population. Given
the relationship between lifestyle factors such as excessive
alcohol intake [25] and smoking habits [26] with
socio-economic disadvantage and lower educational attain-
ment, we were able to extend previous findings by control-
ling for educational attainment as a proxy for lifestyle.
Residual confounding by lifestyle factors is likely. We
modelled residual confounding by calculating the
E-value and found that an unmeasured confounder
would need to have a large risk ratio of at least 39 to ex-
plain away the findings of increased HCC risk. Given the
strong association between alcohol abuse/dependence
and hepatitis C and both PCT and HCC, it is conceiv-
able that unmeasured confounding may explain away
any direct relationship. We were, however, able to iden-
tify persons with a history of chronic alcohol abuse/de-
pendence to further investigate this to partially account
for their generally younger age at the time of death (i.e.,
may have died before they could develop HCC), we con-
ducted a competing risks survival analysis. Results, sug-
gested persons with PCT had a 3-fold excess risk of
HCC even when compared to persons with a history of
alcohol abuse. The remaining high risk, albeit lower than
when comparing to the general population, suggests that
alcohol is an important confounder, but may not com-
pletely explain the association between PCT and HCC.
Interpretation
It has been proposed that the accumulation of uroporpo-
hyrins, of which levels are high in (untreated) PCT, may
cause liver injury, resulting in the formation of a hepatic
tumor [27]. This may occur in parallel or by interaction
with exposure to hepatotoxic factors, such as alcohol.
However, if the increased risk of HCC is related in part to
PCT itself or is due only to confounding lifestyle factors,
is difficult to conclude. Our findings give some support to
the former, given that we observed this increase in the risk
ratio even after controlling for educational attainment and
comparing our cohort to persons with a history of chronic
alcohol abuse/dependence. Of the six persons in our co-
hort with PCT and HCC, two had familial PCT, which is
less associated with other types of liver disease or exces-
sive alcohol intake than sporadic PCT [3]. There was a
trend towards higher concentrations of total porphyrins
and uroporphyrins in PCT patients with HCC compared
to those without. However, the small number of cases and
variability in the findings limit our ability to draw any firm
conclusions. We also observed an increased risk of gall-
bladder and biliary tract cancer in persons with PCT.
However, given we only found three cases and tested over
multiple cancers, this could reflect a chance finding.
Additionally, we found an increased risk of premature
death overall, death byliver diseases and drug or alcohol
overdose in persons with PCT. Liver diseases, such as
chronic hepatitis C virus, are known precipitating factor
for PCT [10, 28], and are also associated with excessive
alcohol intake and injection drug use. We also found
that persons with sporadic PCT were generally more
likely to die from causes associated with lifestyle factors
than persons with familial PCT. Therefore, increased
mortality rates in persons with PCT, and specifically
sporadic PCT, could be caused by lifestyle factors.
Clinical recommendations
According to the European Association for the Study of
the Liver (EASL) and European Organization for Re-
search and Treatment of Cancer (EORTC) clinical prac-
tice guidelines for the management of HCC, an annual
incidence of 1.5% would warrant surveillance of HCC in
cirrhotic patients and 0.2% would warrant surveillance
in non-cirrhotic patients [29]. We found an annual inci-
dence of HCC of 0.07% in our PCT patients, with an
upper bound 95% CI of 0.17%. Additionally, unlike in
acute forms of hepatic porphyria, confounding by con-
current cirrhosis cannot be ruled out in patients with
PCT. Therefore, surveillance cannot be currently recom-
mended based on a PCT diagnosis alone.
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Conclusion
We found that compared to the general population, per-
sons with PCT had a high risk of HCC and death from
alcohol or drug abuse. In addition, they had moderate
excess risks of gallbladder and biliary tract cancers and
of premature death in general. Although it is likely that
most of our findings can be explained by common life-
style risk factors, something inherent in PCT may con-
tribute in part, or by interaction with lifestyle factors, to
the development of HCC.
Additional file
Additional file 1: Table S1. Individual characteristics of persons with
hepatocellular carcinoma and gallbladder and bile duct cancer (DOCX 16 kb)
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